1. Imai N, Tawara I, Yamane M, Muraoka D, Shiku H, Ikeda H. CD4 + T cells support polyfunctionality of cytotoxic CD8 + T cells with memory potential in immunological control of tumor. Cancer Sci. 2020 Jun;111(6):1958-1968. doi: 10.1111/cas.14420.
2. Ishihara M, Tono Y, Miyahara Y, Muraoka D, Harada N, Kageyama S, Sasaki T, Hori Y, Soga N, Uchida K, Shiraishi T, Sato E, Kanda H, Mizuno T, Webster GA, Ikeda H, Katayama N, Sugimura Y, Shiku H. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. Cancer Immunol Immunother. 2020 Apr;69(4):663-675. doi: 10.1007/s00262-020-02483-1.
3. Ishihara M, Kageyama S, Miyahara Y, Ishikawa T, Ueda S, Soga N, Naota H, Mukai K, Harada N, Ikeda H, Shiku H. MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours. BMC Cancer. 2020 Jun 29;20(1):606. doi: 10.1186/s12885-020-07098-4.
4. Sukegawa K, Shitaoka K, Hamana H, Kobayashi E, Miyahara Y, Fujii K, Tsuda K, Saeki S, Nagata T, Ozawa T, Saito S, Fujii T, Muraguchi A, Shiku H, Kishi H. Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer. Eur J Immunol. 2020 Oct;50(10):1580-1590. doi: 10.1002/eji.201948399.
5. Kawamura K, Tanaka Y, Nakasone H, Ishihara Y, Kako S, Kobayashi S, Tanaka Y, Ohmori T, Uchimaru K, Okamoto S, Mineno J, Shiku H, Nishimura S, Kanda Y. Development of a Unique T Cell Receptor Gene-Transferred Tax-Redirected T Cell Immunotherapy for Adult T Cell Leukemia. Biol Blood Marrow Transplant. 2020 Aug;26(8):1377-1385. doi: 10.1016/j.bbmt.2020.04.006.
6. Gong W, Wang L, Stock S, Ni M, Schubert ML, Neuber B, Kleist C, Huckelhoven-Krauss A, Wu D, Muller-Tidow C, Schmitt A, Shiku H, Schmitt M, Sellner L. Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells. Cells. 2021 Jan 14;10(1):152. doi: 10.3390/cells10010152.
7. Ishikawa T, Kageyama S, Miyahara Y, Okayama T, Kokura S, Wang L, Sato E, Yagita H, Itoh Y, Shiku H. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. Cancer Immunol Immunother. 2021 Mar 22. doi: 10.1007/s00262-021-02892-w. Online ahead of print.